PF-07985045 + pembrolizumab

PF-07985045 + pembrolizumab is an investigational combination therapy for advanced solid tumors, comprising PF-07985045, a novel small molecule inhibitor of KRAS-mutant cancers, and pembrolizumab, a marketed monoclonal antibody that inhibits the immune checkpoint receptor PD-1. PF-07985045 directly targets KRAS mutations frequently found in cancers such as non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma, aiming to block oncogenic KRAS signaling and inhibit tumor cell proliferation[3][4][5]. Pembrolizumab (Keytruda) acts as a checkpoint inhibitor, blocking PD-1 on T cells to enhance anti-tumor immune responses. The combination is being tested in phase 1 trials to evaluate safety, tolerability, optimal dosing, and preliminary efficacy, with PF-07985045 administered orally and pembrolizumab intravenously[1][2][3][4][8].

Other names

pembrolizumab